Abstract
MM is an incurable cancer in the bone marrow. The treatment of MM has
developed significantly during the last 20 years, which has resulted in
increased survival. Daratumumab is the first CD38 antibody approved for
treatment of MM. It has improved the treatment of MM even further. This
is an evaluation of the modes of action of daratumumab and a description
of the development of resistance with focus on inhibitory checkpoint
receptors on CD8+ T-cells, complement activation and extracellular
vesicles.